The GLP-1RAs liraglutide and semaglutide reduce cardiovascular risk in type 2 diabetes patients. 
HIGHLIGHTS
The GLP-1RAs liraglutide and semaglutide reduce cardiovascular risk in type 2 diabetes patients. with the exception of thrombosis (16, 20) .
In ApoE
The aim of these studies was to specifically eval- NanoString ASSAY. NanoString gene analysis was performed using a custom-made code set consisting of probes for 275 genes of interest (catalog GXA-P1CS-576, AME Bioscience, Thurleigh, United Kingdom) and a master kit containing all necessary buffers and reagents (catalog NAA-AKIT-192, AME Bioscience).
Following hybridization, excess probes were removed, and probe/target complexes were aligned and immobilized on a cartridge by the GEN2 nCounter PrepStation (NanoString, Seattle, Washington), using high-sensitivity settings and finally scanned using the GEN2 nCounter digital analyzer (NanoString), using maximum screening intensity (555 fields of view). 
Rakipovski et al. Figure 1 .
Liraglutide and Semaglutide Reduce Atherosclerosis Figure 1D ). In both mouse models, semaglutide administration resulted in a significant dosedependent decrease in BW (Figure 2) , whereas the attenuating effect on aortic plaque lesions was similar at all dose levels ( Figure 1D ) and thus did not correlate with the degree of BW lowering. T-chol ¼ total cholesterol; TG ¼ triglyceride; WD ¼ Western diet.
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Liraglutide and Semaglutide Reduce Atherosclerosis (23), and semaglutide prevented the WDinduced changes in genes related to inflammatory markers at all dose levels ( Figure 5C ).
DISCUSSION
The CV risk reduction (RR) observed using the GLP1RAs liraglutide and semaglutide in the LEADER and SUSTAIN-6 trials is proposed to be mediated through antiatherosclerotic mechanisms (6, 7, 9) . GLP1RAs are potent regulators of BW, hyperglycemia, and to some extent dyslipidemia (10) . In the studies presented here, semaglutide exerted antiatherosclerotic efficacy at doses that did not lower BW significantly (Figures 1 and 2) , indicating that the antiatherosclerotic effects cannot be attributed solely to prevention of gain in BW. These observations were further supported by the weight-matched comparator study in ApoE À/À mice, where only liraglutide decreased the plaque lesion development (Figure 3) , and in an acute inflammation study in Rakipovski et al.
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Liraglutide and Semaglutide Reduce Atherosclerosis Whether CV protection is a class effect for all longacting GLP-1RAs will thus be further clarified when the REWIND trial is reported.
STUDY LIMITATIONS. Investigating interventions affecting the development of atherosclerosis in murine models often leads to discussions of the validity and translational value of the findings to humans.
The lack of plaque rupture and thrombosis and the subsequent effect on the heart or cerebral ischemia have often led to questions of the relevance of these models for validation of novel pharmaceuticals in the field of CV disease (52) . A recent study by Pasterkamp et al. (53) reported discrepancies in comparing regulation of murine versus human genes in the development of atherosclerosis, and it was suggested that a sensible way to improve the translational value was to group genes related to specific pathways. In the studies presented here, there shown in Figure 6 . The antiatherosclerotic effect of Uncorrected and Benjamini-Hochberg-corrected p values for Figures 5B and 5C can be found in Supplemental Table S4 . TG ¼ triglyceride.
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